Image of Gail H Cassell

Gail H Cassell, Ph.D.

Dr. Cassell is vice president for TB Drug Development at the Infectious Disease Research Institute in Seattle, Washington, professor emeritus and former chair, Department of Microbiology, University of Alabama at Birmingham, and former vice president for scientific affairs and distinguished Lilly research scholar for infectious diseases at Eli Lilly and Company in Indianapolis, Indiana. She founded the Forum on Drug Discovery, Development and Translation, which she continues to co-chair, at the Institute of Medicine. She has a distinguished record of national service with the National Academy of Sciences, National Institutes of Health, Centers for Disease Control, and several other national and international institutions.

Affiliations:

Division of Global Health Equity, Brigham and Women's Hospital

Dr. Cassell is a leader on efforts to address multidrug-resistant tuberculosis (MDRTB). She and Barry Bloom, former dean of Harvard School of Public Health, co-lead an Institute of Medicine project on drug supply chain issues related to MDRTB. She actively advises numerous government agencies, NGOs, and foundations on the scale-up of MDRTB diagnosis and treatment in endemic areas around the world, including in Russia. Dr. Cassell is advising the GHSM Sentinel Project on pediatric drug-resistant tuberculosis, a global partnership that aims to develop and deploy evidence-based strategies to prevent child deaths from drug-resistant tuberculosis.

Cytopathogenicity of Mycoplasma fermentans (including strain incognitus).
Authors: Authors: Stadtländer CT, Watson HL, Simecka JW, Cassell GH.
Clin Infect Dis
View full abstract on Pubmed
A primate model of Ureaplasma urealyticum infection in the premature infant with hyaline membrane disease.
Authors: Authors: Walsh WF, Butler J, Coalson J, Hensley D, Cassell GH, deLemos RA.
Clin Infect Dis
View full abstract on Pubmed
Use of the polymerase chain reaction for detection of Mycoplasma fermentans and Mycoplasma genitalium in the urogenital tract and amniotic fluid.
Authors: Authors: Blanchard A, Hamrick W, Duffy L, Baldus K, Cassell GH.
Clin Infect Dis
View full abstract on Pubmed
Interactions of mycoplasmas with B cells: antibody production and nonspecific effects.
Authors: Authors: Simecka JW, Ross SE, Cassell GH, Davis JK.
Clin Infect Dis
View full abstract on Pubmed
Radiographic changes associated with tracheal isolation of Ureaplasma urealyticum from neonates.
Authors: Authors: Crouse DT, Odrezin GT, Cutter GR, Reese JM, Hamrick WB, Waites KB, Cassell GH.
Clin Infect Dis
View full abstract on Pubmed
Systemic neonatal infection due to Ureaplasma urealyticum.
Authors: Authors: Waites KB, Crouse DT, Cassell GH.
Clin Infect Dis
View full abstract on Pubmed
Therapeutic considerations for Ureaplasma urealyticum infections in neonates.
Authors: Authors: Waites KB, Crouse DT, Cassell GH.
Clin Infect Dis
View full abstract on Pubmed
Ureaplasma urealyticum and chronic lung disease of prematurity: critical appraisal of the literature on causation.
Authors: Authors: Wang EE, Cassell GH, Sánchez PJ, Regan JA, Payne NR, Liu PP.
Clin Infect Dis
View full abstract on Pubmed
Three views on faculty tenure in medical schools.
Authors: Authors: Jones RF, Friedman PJ, Cassell GH, Cooper RA.
Acad Med
View full abstract on Pubmed
Detection of Ureaplasma urealyticum by polymerase chain reaction in the urogenital tract of adults, in amniotic fluid, and in the respiratory tract of newborns.
Authors: Authors: Blanchard A, Hentschel J, Duffy L, Baldus K, Cassell GH.
Clin Infect Dis
View full abstract on Pubmed